Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

Hoang, Tien; Kim, KyungMann; Jaslowski, Anthony J.; Koch, Paul L.; Beatty, Peter A.; McGovern, James; Quisumbing, Maria; Shapiro, Gary R.; Witte, Robert S.; Schiller, Joan H.

doi:10.1016/s0169-5002(03)00273-3

Cited by 56 publications

(29 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median TTP and MST for refractory relapsed SCLC were 5.6 weeks (range 3-24.5 weeks) and 4.2 months (range 1.5-13.0 months) respectively. Although the authors concluded that the efficacy of gemcitabine alone should be limited to recurrent SCLC as second-line chemotherapy [Hoang et al 2003], the data were not sufficient to support this conclusion. Amrubicin is a fully synthetic 9 aminoanthracycline, converted in the body to amrubicinol by reduction of the 13-position ketone, possessing higher antitumor activity than the parent molecule.…”

Section: Cytotoxic Agentsmentioning

confidence: 99%

Relapsed small cell lung cancer: treatment options and latest developments

et al. 2014

View full text Add to dashboard Cite

According to recent analyses, there was a modest yet significant improvement in median survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North America, Europe, Japan and other countries over the last 30 years. The median survival time of limited stage SCLC is 15-20 months and 5-year survival rate is 15% or less. In terms of extensive stage SCLC, a median survival time of 9.4-12.8 months and 2-year survival of 5.2-19.5% are still disappointing. Despite being highly sensitive to first-line chemotherapy and radiotherapy treatments, most patients with SCLC experience relapse within 2 years and die from systemic metastasis. While several clinical trials of cytotoxic chemotherapies and molecular targeting agents have been investigated in the treatment of relapsed SCLC, none showed a significant clinical activity to be able to exceed topotecan as second-line chemotherapy. There are problematic issues to address for relapsed SCLC, such as standardizing the treatment for third-line chemotherapy. Topotecan alone was the first approved therapy for second-line treatment for relapsed SCLC. Amrubicin is a promising drug and a variety of trials evaluating its efficacy have been carried out. Amrubicin has shown superiority to topotecan in a Japanese population, but was not superior in a study of western patients. There are some controversial issues for relapsed SCLC, such as treatment for older patients, third-line chemotherapy and efficacy of molecular targeting therapy. This article reviews current standard treatment, recent clinical trials and other topics on relapsed SCLC.

show abstract

Section: Cytotoxic Agentsmentioning

confidence: 99%

Relapsed small cell lung cancer: treatment options and latest developments

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The rare exceptions in this regard have been the evaluation of anti-chondroitin sulfate proteoglycan 9.2.27 surface marker daunorubicin conjugates against chemotherapeuticresistant M21 metastatic melanoma; 36,38,101 anthracycline conjugates of epidermal growth factor (EGF) or an EGF fragment evaluated for their anti-neoplastic potency against chemotherapeutic-resistant MCF-7AdrR mammary carcinoma; 102 and epirubicin-(anti-HER2/ neu) or epirubicin-(anti-EGFR) potency assessed against chemotherapeutic-resistant SKBr-3 mammary carcinoma. 10 In this context, measurement of gemcitabine-(carbamate)-[anti-HER2/neu] cytotoxic anti-neoplastic potency could also have been determined in an entirely different neoplastic cell type such as pancreatic carcinoma, 103 small-cell lung carcinoma, 104 neuroblastoma, 105 or leukemia/lymphoid 72,106 populations due to their relatively high gemcitabine sensitivity. Similarly, human promyelocytic leukemia, 61,72 T-4 lymphoblastoid clones, 72 glioblastoma; 61,72 cervical epithelioid carcinoma, 72 colon adenocarcinoma, 72 pancreatic adenocarcinoma, 72 pulmonary adenocarcinoma, 72 oral squamous cell carcinoma, 72 and prostatic carcinoma 30 have been found to be sensitive to gemcitabine and gemcitabine-(oxyether phospholipid) covalent chemotherapeutic conjugates.…”

Section: Cytotoxicitymentioning

confidence: 99%

Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma

Coyne

Jones

Pharr

2011

Bioorganic & Medicinal Chemistry

137

View full text Add to dashboard Cite

“…Several other cytotoxic agents, including taxanes, gemcitabine, vinorelbine, irinotecan and pemetrexed, have been investigated as second-line treatment, in either single-agent or combination treatment (table 3) [41,65,[76][77][78][79][80][81][82][83][84][85][86][87][88][89][90]. Some agents, such as paclitaxel and irinotecan, have shown some degree of activity in phase II trials.…”

Section: Second-line Treatment For Es-sclcmentioning

confidence: 99%

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

Demedts

Vermaelen²,

Meerbeeck³

2009

European Respiratory Journal

183

162

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with cigarette smoking, with patients often presenting with metastatic disease at the time of diagnosis. Although SCLC is very chemoradiosensitive and high response rates are obtained with treatment, relapse rates are high and the prognosis remains very poor.In limited-stage SCLC, the overall survival rate has been significantly improved by adding dosehyperfractionated thoracic radiotherapy and prophylactic cranial irradiation to systemic chemotherapy. In contrast, little progress has been made in the treatment of extensive-stage SCLC (ES-SCLC), apart from the recently documented survival gain by the addition of prophylactic cranial irradiation.First-line therapy in ES-SCLC currently consists of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative.New treatments are needed in order to improve the prognosis of ES-SCLC, as median survival with current standard treatment is still only 9-10 months from diagnosis. The present review focuses on the management of ES-SCLC, with special attention to the development of new treatment options.KEYWORDS: Chemotherapy, extensive disease, radiotherapy, small cell lung cancer, treatment S mall cell lung cancer (SCLC) is an aggressive malignant disease, with the majority of patients presenting with distant metastasis at diagnosis. A separate staging system has been developed for SCLC, classifying SCLC as limited or extensive disease [1]. The International Association for the Study of Lung Cancer defines limited-stage SCLC (LS-SCLC) as: ''disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral pleural effusion independent of whether cytology is positive or negative '' [2]. Patients with SCLC who do not fit this definition are considered to have extensive-stage SCLC (ES-SCLC). This staging system was used to select the appropriate treatment regimen: chemotherapy in combination with thoracic radiotherapy in patients with LS-SCLC, and chemotherapy alone in patients with ES-SCLC. Recent data suggest that the tumour, node, metastasis classification traditionally reserved for the staging of nonsmall cell lung cancer (NSCLC) can also be applied for the staging of SCLC [3].

show abstract

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

Cited by 56 publications

References 14 publications

Relapsed small cell lung cancer: treatment options and latest developments

Relapsed small cell lung cancer: treatment options and latest developments

Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma

Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

Contact Info

Product

Resources

About